Clinical trials: Gefitinib, completed
Solid Tumors, Lymphoma
A Study of LY2875358 in Japanese Participants With Advanced Cancer
The purpose of this study is to assess the safety and tolerability of LY2875358 in Japanese participants with cancer that is advanced and/or may have spread to another part of the body.
- Conditions
- Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01602289
- Testing
- LY2875358, Erlotinib, Gefitinib
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- FLAURA (NCT02296125)
- Testing
- Erlotinib 150/100 mg, Gefitinib 250 mg
- Where
- 170 sites in United States, Australia and 28 more
- Volunteers
- 674 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
- Trial name
- NCT00080340
- Testing
- TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
- Where
- 338 sites in United States, Argentina and 6 more
- Volunteers
- 520 people
- Sponsor
- Telik
Overal Survival, Non-small Cell Lung Cancer
Bone Metastasis on the Survival of Gefitinib Effective Patients
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective…
- Trial name
- NCT03157310
- Testing
- Gefitinib
- Volunteers
- 265 people
- Sponsor
- Qilu Hospital of Shandong University
Neuroblastoma
Therapy for Children With Neuroblastoma
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell…
- Trial name
- NCT00135135
- Testing
- Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid, Radiation therapy, Surgery, Peripheral Stem cell transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- St. Jude Children's Research Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
Phase II trial to study the effectiveness of gefitinib in treating patients who have advanced unresectable hepatocellular carcinoma (liver cancer).
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00071994
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Patients presenting a deterioration of the general state (performance status [PS] 2-3), constitute a population which needs an adapted treatment.
- Trial name
- NCT00198393
- Testing
- Gefitinib, gemcitabine, Docetaxel
- Where
- 2 sites in France
- Volunteers
- 126 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
This randomized phase III trial studies how well gefitinib works in treating patients with stage IB, II, or IIIA non-small cell lung cancer that was completely removed by surgery.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00049543
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 503 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tolerance of these treatments.
- Trial name
- NCT00333294
- Testing
- Gefitinib, Radiation therapy, Cisplatin
- Where
- 4 sites in France
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
The purpose of this study is to assess the efficacy and safety of gefitinib in patients who have progressed on first line gefitinib, comparing continuing gefitinib in addition to cisplatin plus pemetrexed combination chemotherapy…
- Trial name
- IMPRESS (NCT01544179)
- Testing
- Gefitinib, Pemetrexed, Cisplatin
- Where
- 61 sites in China, France and 9 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or…
- Trial name
- NCT00095836
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Squamous Cell Carcinoma of the Head and Neck
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
- Trial name
- NCT00206219
- Testing
- Gefitinib, methotrexate
- Where
- 109 sites in United States, Argentina and 23 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Iressa Case Control Study in Japan
The purposes of this study are: To estimate the relative risk of ILD in advanced/recurrence NSCLC patients treated with gefitinib as compared to other chemotherapy treatment, and to assess the risk factors for ILD in…
- Trial name
- NCT00252759
- Where
- 44 sites in Japan
- Volunteers
- 6,000 people
- Sponsor
- AstraZeneca
Lung Cancer, Metastatic Cancer
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00238251
- Testing
- gefitinib, temozolomide, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 59 people
- Sponsor
- Swiss Cancer Institute
Glioblastoma, Rhabdomyosarcomas
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects.
- Conditions
- Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00132158
- Testing
- Irinotecan (Camptosar), Gefitinib (Iressa)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- St. Jude Children's Research Hospital
Carcinoma, Non-Small Cell-Lung, Lung Neoplasms
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
During Phase 1b portion, there will be a dose-escalation of AV-299 (formerly SCH 900105) in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor.
- Conditions
- Carcinoma, Non-Small Cell-Lung, Lung Neoplasms, Lung Cancer, Respiratory Tract Neoplasms
- Trial name
- NCT01039948
- Testing
- AV-299 + gefitinib, Gefitinib
- Where
- 26 sites in Hong Kong, Malaysia and 5 more
- Volunteers
- 203 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of…
- Trial name
- IPASS (NCT00322452)
- Testing
- Gefitinib, Carboplatin, Paclitaxel
- Where
- 56 sites in China, Hong Kong and 7 more
- Volunteers
- 1,329 people
- Sponsor
- AstraZeneca
Lung Cancer, Non-small Cell Lung Cancer
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
The purpose of this research study is to: see if gefitinib pills can shrink Stage 1 or 2 non-small cell lung cancers before surgery see if your non-small cell lung cancer has a mutation in a certain part of the EGFR gene see if…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
- Trial name
- NCT00588445
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in addition to the standard chemotherapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium by estimating…
- Trial name
- NCT00246974
- Testing
- Gemcitabine, Cisplatin, Gefitinib
- Where
- 14 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AstraZeneca